Nucleotide analogs
View Patent ↗The invention provides for nucleotide analogs and methods of using the same, e.g., for sequencing nucleic acids.
1. A nucleotide analog of the following Formula II:
wherein
NTP is a nucleoside or nucleotide triphosphate, or an analog thereof, capable of incorporating onto the 3′ end of a polynucleotide strand hybridized to a template presenting the complement of the NTP;
L is a detectable label that facilitates the identification of the nucleotide analog;
Inhibitor comprises (a) one or more multiply charged groups or groups capable of becoming multiply charged, or (b) two or more singly charged groups or two or more groups capable of becoming singly charged;
R 1 comprises a cleavable bond, which upon cleavage results in de-association of NTP from both L and Inhibitor;
R 2 is a tri-valent radical having the formula:
wherein
R 2 ′ is a tri-valent radical, and
R 2 ″ is a bi-valent radical selected from:
—(CH 2 ) x —, —(CH 2 —O) x —, —(CH 2 —O) z —(CH 2 ) y —, —(CH 2 ) z —(CH 2 —O) y —,
and the same substituted with one or more groups selected from hydroxyl, halogen, amino, thiol, (C 1 -C 6 ) alkyl, wherein x, y and z are each integers with x and y+z are each from 2 to 10;
R 3 is a bond or group linking R 2 to the Inhibitor moiety; and
R 4 is a bond or group linking R 2 to a L.
2. The nucleotide analog of claim 1 , wherein the Inhibitor comprises a charged group selected from the group consisting of —COOH and —PO 4 .
3. The nucleotide analog of claim 1 , wherein the Inhibitor comprises at least two —COOH groups.
4. The nucleotide analog of claim 1 , wherein the Inhibitor does not comprise an —PO 4 group.
5. The nucleotide analog of claim 1 , wherein the Inhibitor does not comprise a n aryl group.
6. The nucleotide analog of claim 1 , wherein the Inhibitor comprises a group selected from the group consisting of Glu, Asp, Arg, His, Thr, Trp, Gln, Tyr, Pro and Lys.
7. The nucleotide analog of claim 1 , wherein R 1 comprises a C—C triple bond or a trans C—C double bond.
8. The nucleotide analog of claim 1 , wherein R 1 comprises a S—S bond.
9. The nucleotide analog of claim 1 , wherein R 1 comprises a C—C triple bond and a S—S bond.
10. The nucleotide analog of claim 1 , wherein R 1 comprises
wherein R 6 is a H or an alkyl group; q and r independently is an integer from about 1 to about 10.
11. The nucleotide analog of claim 10 , wherein q is 1 or 2 and r is 1, 2 or 3.
12. The nucleotide analog of claim 1 , wherein NTP is selected from dATP, dGTP, dCTP, dTTP, dUTP, ATP, GTP, CTP, TTP, UTP or an analog thereof.
13. The nucleotide analog of claim 1 , wherein the L is an optically-detectable moiety.
14. The nucleotide analog of claim 13 , wherein the optically-detectable moiety comprises a fluorophore.
15. The nucleotide analog of claim 14 , wherein the fluorophore is Cy5 or ATTO 647N.
16. The nucleotide analog of claim 1 , wherein R 3 comprises
wherein R 1 is H or alkyl groups, and may together form 3, 4, 5, or 6-member rings.
17. The nucleotide analog of claim 16 , wherein R 3 comprises
wherein R 4 is Glu, Asp, Arg, His, Thr, Trp, Gln, Tyr, Pro or Lys, or a peptide of two or more amino acids comprising an amino acid selected from the group consisting of Glu, Asp, Arg, His, Thr, Trp, Gln, Tyr, Pro and Lys.
18. The nucleotide analog of claim 1 , selected from:
19. A method for sequencing a nucleic acid, the method comprising the steps of:
exposing a nucleic acid duplex comprising a template portion and a primer portion to a nucleotide analog of the following Formula II:
detecting incorporation of the analog;
removing or neutralizing the inhibitor; and
repeating the exposing, detecting, and removing steps at least once, thereby to determine the sequence of the template,
wherein
NTP is a nucleoside or nucleotide triphosphate, or an analog thereof, capable of incorporating onto the 3′ end of a polynucleotide strand hybridized to a template presenting the complement of the NTP;
L is a detectable label that facilitates the identification of the nucleotide analog;
Inhibitor comprises (a) one or more multiply charged groups or groups capable of becoming multiply charged, or (b) two or more singly charged groups or two or more groups capable of becoming singly charged;
R 1 comprises a cleavable bond, which upon cleavage results in de-association of NTP from both L and Inhibitor;
R 2 is a tri-valent radical having the formula:
wherein
R 2 ′ is a tri-valent radical, and
R 2 ″ is a bi-valent radical selected from:
—(CH 2 ) x —, —(CH 2 —O) x —, —(CH 2 —O) z —, —(CH 2 ) y —, —(CH 2 ) z —(CH 2 —O) y —,
and the same substituted with one or more groups selected from hydroxyl, halogen, amino, thiol, (C 1 -C 6 ) alkyl, wherein x, y and z are each integers with x and y+z are each from 2 to 10;
R 3 is a bond or group linking R 2 to the Inhibitor moiety; and
R 4 is a bond or group linking R 2 to a L.
20. The method of claim 19 , wherein the inhibitor is selected from the group consisting of one or more carboxylic acid, one or more phosphate, one or more amino acid, one or more peptide, one or more sulfate, one or more caproic acid, and any combination thereof.